Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/97581
Title: TGF-β1 and TGF-β2 abundance in liver diseases of mice and men
Author: Dropmann, Anne
Dediulia, Tatjana
Breitkopf-Heinlein, Katja
Korhonen, Hanna
Janicot, Michel
Weber, Susanne N.
Thomas, Maria
Piiper, Albrecht
Bertran Rodríguez, Esther
Fabregat Romero, Isabel
Abshagen, Kerstin
Hess, Jochen
Angel, Peter
Coulouarn, Cédric
Dooley, Steven
Meindl-Beinker, Nadja M.
Keywords: Malalties del fetge
Fibrosi quística
Ratolins (Animals de laboratori)
Regeneració (Biologia)
Liver diseases
Cystic fibrosis
Mice (Laboratory animals)
Regeneration (Biology)
Issue Date: 21-Jan-2016
Publisher: Impact Journals
Abstract: TGF-β1 is a major player in chronic liver diseases promoting fibrogenesis and tumorigenesis through various mechanisms. The expression and function of TGF-β2 have not been investigated thoroughly in liver disease to date. In this paper, we provide evidence that TGF-β2 expression correlates with fibrogenesis and liver cancer development. Using quantitative realtime PCR and ELISA, we show that TGF-β2 mRNA expression and secretion increased in murine HSCs and hepatocytes over time in culture and were found in the human-derived HSC cell line LX-2. TGF-β2 stimulation of the LX-2 cells led to upregulation of the TGF-β receptors 1, 2, and 3, whereas TGF-β1 treatment did not alter or decrease their expression. In liver regeneration and fibrosis upon CCl4 challenge, the transient increase of TGF-β2 expression was accompanied by TGF-β1 and collagen expression. In bile duct ligation-induced fibrosis, TGF-β2 upregulation correlated with fibrotic markers and was more prominent than TGF-β1 expression. Accordingly, MDR2-KO mice showed significant TGF-β2 upregulation within 3 to 15 months but minor TGF-β1 expression changes. In 5 of 8 hepatocellular carcinoma (HCC)/hepatoblastoma cell lines, relatively high TGF-β2 expression and secretion were observed, with some cell lines even secreting more TGF-β2 than TGF-β1. TGF-β2 was also upregulated in tumors of TGFα/cMyc and DEN-treated mice. The analysis of publically available microarray data of 13 human HCC collectives revealed considerable upregulation of TGF-β2 as compared to normal liver. Our study demonstrates upregulation of TGF-β2 in liver disease and suggests TGF-β2 as a promising therapeutic target for tackling fibrosis and HCC.
Note: Reproducció del document publicat a: http://dx.doi.org/10.18632/oncotarget.6967
It is part of: Oncotarget, 2016, vol. 7, num. 15, p. 19499-19518
Related resource: http://dx.doi.org/10.18632/oncotarget.6967
URI: http://hdl.handle.net/2445/97581
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
657826.pdf2.65 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons